Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence.
Blood–brain barrier
Brain
Nanomedicine
Peptides
Targeting
Journal
Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
04
2020
revised:
22
04
2020
accepted:
22
05
2020
pubmed:
2
6
2020
medline:
16
7
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
Central nervous system (CNS) compartments remain one of the most difficult districts for drug delivery. This is due to the presence of the blood-brain barrier (BBB) that hampers 90% of drug passage, dramatically requiring non-invasive treatment strategies. Here, for the first time, the use of opioid-derived deltorphin-derivative peptides to drive biodegradable and biocompatible polymeric (i.e. poly-lactide-co-glycolide, PLGA) nanomedicines delivery across the BBB was described. Opioid-derived peptides were covalently conjugated to furnish activated polymers which were further used for fluorescently tagged nanoformulations. Beyond reporting production, formulation methodology and full physico-chemical characterization, in vivo tests generated clear proof of BBB crossing and CNS targeting by engineered nanomedicines opening the research to further applications of drug delivery and targeting in CNS disease models.
Identifiants
pubmed: 32479916
pii: S1549-9634(20)30080-0
doi: 10.1016/j.nano.2020.102226
pii:
doi:
Substances chimiques
Oligopeptides
0
Peptides
0
deltorphin
119975-64-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102226Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.